News & Blog
News & Blog
Job Opening – Accounting Specialist
FARA Advocates for Effective Inclusion of Children Early in Clinical Trials at Pediatric Inclusion Roundtable
2023 Donor Impact Report
LEXEO Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
C-Path Partners with FARA to Fortify RDCA-DAP and Further Accelerate Drug Development with new Friedreich’s Ataxia Data
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data Ongoing open l...
The Oxford-Harrington Rare Disease Centre Announces Newly Funded Grant Award Programmes to Develop New Therapies for Friedreich’s Ataxia
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Astellas shares that US FDA cleared their IND with Fast Track designation for Phase 1 trial of their investigational gene therapy for the treatment of cardiomyopathy in FA
In a communication to FARA and the FA Community, Astellas shared that the US FDA has cleared their Investigational New Drug with a fast ...